8-K: FitLife Brands Q3 Revenue Jumps 47% on Irwin Acquisition

FitLife Brands reported a 47% revenue increase to $23.5 million in Q3 2025, largely driven by the recent acquisition of Irwin Naturals, despite a decline in net income and gross margin.

Summary

• Total revenue increased 47% to $23.5 million for Q3 2025, up from $16.0 million in Q3 2024.
• The acquisition of Irwin Naturals, completed on August 8, 2025, contributed $6.8 million to the Q3 revenue.
• Wholesale revenue surged 156% to $13.2 million, representing 56% of total revenue.
• Online revenue decreased 5% to $10.3 million, accounting for 44% of total revenue.
• Net income declined to $0.9 million from $2.1 million in Q3 2024, primarily due to acquisition-related transaction expenses, lower gross margin, and higher income tax expense.
• Basic earnings per share fell to $0.10 from $0.23, and diluted earnings per share to $0.09 from $0.21.
• Adjusted EBITDA increased 6% to $3.8 million.
• Gross margin decreased to 37.2% from 43.8% in Q3 2024, though it would have been 38.9% excluding inventory step-up amortization from the Irwin acquisition.
• MusclePharm revenue grew 55%, with wholesale revenue up 112%, but gross margin was adversely affected by increasing whey protein costs and promotional incentives.
• Legacy FitLife (excluding MRC) saw an 8% increase in total revenue, with wholesale up 3% and online up 14%.
• MRC online revenue declined by 16%, contributing to an 8% decrease in online revenue for other brands (excluding Irwin).

Sentiment

Score: 5

Explanation: The filing presents a mixed bag. While revenue growth is strong due to the acquisition, profitability metrics (net income, EPS, gross margin) have declined. The acquisition introduces new opportunities but also integration challenges and increased debt. Concerns about rising protein costs and consumer weakness temper optimism.

Positives

• Total revenue increased significantly by 47% to $23.5 million, largely due to the Irwin Naturals acquisition.
• Wholesale revenue saw substantial growth of 156% to $13.2 million.
• MusclePharm brand revenue increased 55%, with wholesale revenue up 112%, indicating strong channel growth.
• Legacy FitLife (excluding MRC) demonstrated organic revenue growth of 8% in Q3 2025 and 7% year-to-date.
• Adjusted EBITDA increased by 6% to $3.8 million, showing operational profitability improvement.
• Irwin Naturals' Amazon sales, which commenced on October 11, 2025, are showing consistent daily increases, currently around $10,000 per day, or approximately $3.6 million on an annualized basis.
• The company is actively working to capture supply chain and SG&A efficiencies at Irwin, with cost cuts implemented in Q3 expected to impact Q4 2025 and beyond.

Negatives

• Net income decreased significantly to $0.9 million from $2.1 million in Q3 2024.
• Basic EPS declined to $0.10 from $0.23, and diluted EPS to $0.09 from $0.21.
• Gross margin decreased to 37.2% from 43.8% in Q3 2024, even when excluding the inventory step-up, it was 38.9% compared to 43.8%.
• Online revenue decreased by 5% overall, with online revenue for other brands (excluding Irwin) declining 8%.
• MRC business continues to face challenges, with online revenue declining 16%.
• MusclePharm's gross margin and contribution as a percentage of revenue were adversely affected by increasing whey protein costs and promotional incentives.
• Cash and cash equivalents decreased to $3.512 million as of September 30, 2025, from $4.468 million at December 31, 2024.
• Net cash provided by operating activities decreased to $7.195 million for the nine months ended September 30, 2025, from $8.653 million in the prior year period.

Risks

• Increasing cost of whey protein, primarily affecting the MusclePharm brand, which the company is currently absorbing to gain market share.
• General consumer weakness, evidenced by declining customer counts in brick-and-mortar retailers and consumer sentiment benchmarks near all-time lows, creating uncertain near-term effects.
• Challenges associated with the integration and performance of acquired brands, specifically Irwin Naturals, including rectifying out-of-stock issues and capturing expected efficiencies.
• Ongoing challenges with the MRC business, including driving off-Amazon revenue and increasing traffic to Amazon listings.
• The ability of the company to continue to grow revenue, achieve positive cash flow, and service its debt, as stated in forward-looking statements.
• Fluctuations in gross margin and contribution margin for MusclePharm due to promotional efforts and raw material costs.

Future Outlook

Management anticipates continued increased promotional efforts for MusclePharm. The company may implement price increases for MusclePharm products to offset rising protein costs. They expect to become the primary seller on all Irwin product listings on Amazon as other sellers deplete inventory. Management is hopeful for greater stability for the MRC business in early 2026 as it laps initial revenue declines for the Dr. Tobias brand. Near-term effects of increasing whey protein costs and general consumer weakness are uncertain.

Management Comments

• "Although we are still working through the previously disclosed challenges associated with our MRC business, we are very encouraged by the performance of our other brands during the third quarter of 2025, with MusclePharm organic revenue increasing 55% and Legacy FitLife organic revenue excluding MRC increasing 8%."
• "We are pleased with the strong revenue performance of the MusclePharm brand, with wholesale revenue increasing 112% on a year-over-year basis during the quarter."
• "Margins for this business were lower during the quarter, primarily due to increasing protein costs, which we are currently choosing to absorb as we continue to fight for increased distribution and sell-through."
• "Irwin is also off to a good start. As is the case with all acquisitions, there are a number of challenges that we are working through, but these challenges also represent opportunities for improved performance and we remain excited about the Irwin brands and their potential."
• "Our primary concerns right now relate to the increasing cost of whey protein, which primarily affects our MusclePharm brand, and general consumer weakness."
• "Although we remain optimistic about our brands and their long-term potential, these factors have an uncertain near-term effect."

Industry Context

The nutritional supplements and wellness products industry is experiencing both growth (driven by acquisitions and wholesale channels) and challenges (rising raw material costs like whey protein, and broader consumer weakness impacting online sales and brick-and-mortar traffic). FitLife Brands' strategy of acquiring complementary brands like Irwin Naturals aligns with industry consolidation trends, while its efforts to absorb costs for market share reflect competitive pressures. The shift in online sales strategy for Irwin (from wholesale partner to direct on Amazon) indicates an adaptation to evolving e-commerce dynamics.

Stakeholder Impact

• Shareholders: Experience diluted earnings per share and lower net income, but also significant revenue growth and strategic expansion through acquisition. Increased debt levels could be a concern.
• Customers: May face potential price increases for MusclePharm products due to rising raw material costs. Irwin customers may see a shift in online purchasing channels (direct from FitLife on Amazon).
• Employees: Potential for integration challenges and cost-cutting measures at acquired entities like Irwin Naturals.
• Suppliers: Whey protein suppliers may see increased demand from MusclePharm, potentially leading to higher costs for FitLife.
• Creditors: Increased debt from term loans and revolving credit line, indicating higher leverage.

Next Steps

• Continue increased promotional efforts for the MusclePharm brand.
• Potentially implement price increases for MusclePharm products to offset rising protein costs.
• Work towards becoming the primary seller on all Irwin product listings on Amazon.
• Capture supply chain and SG&A efficiencies at Irwin, with further cost cuts impacting Q4 2025 and beyond.
• Rectify out-of-stock issues and increase focus on new product development at Irwin.
• Work on initiatives to generate revenue off-Amazon for MRC and drive additional traffic to Amazon listings.
• Hold an investor conference call on November 13, 2025, at 4:30 pm ET.

Key Dates

Recommendation

The significant revenue growth driven by the Irwin acquisition is a positive, indicating strategic expansion. However, the decline in net income, EPS, and gross margin, coupled with increased debt to finance the acquisition, presents a mixed financial picture. While management is addressing challenges and sees opportunities, concerns about rising protein costs and general consumer weakness introduce near-term uncertainty. A "hold" recommendation reflects the balance between growth potential from acquisitions and operational challenges impacting profitability and cash flow, suggesting investors monitor integration progress and margin trends before making further commitments.

Keywords

Nutritional Supplements, Wellness Products, FitLife Brands, FTLF, Irwin Naturals Acquisition, Q3 2025 Earnings, Wholesale Revenue Growth, Online Revenue Decline, Gross Margin, Adjusted EBITDA, MusclePharm, MRC, Whey Protein Costs, Consumer Weakness, SEC Filing, 8-K